Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Brian Abel

Showing results (31-40 of 36) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 36 results.
Exercise Immunology Review|February 13, 2019
Hallmarks of improved immunological responses in the vaccination of more physically active elderly femalesGlenn Choon Lim Wong, Vipin Narang, Yanxia Lu, et al.
Biorxiv : the Preprint Server for Biology|October 14, 2020
CD8+ T cell responses in convalescent COVID-19 individuals target epitopes from the entire SARS-CoV-2 proteome and show kinetics of early differentiationHassen Kared, Andrew D Redd, Evan M Bloch, et al.
The Journal of Clinical Investigation|January 11, 2021
SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individualsHassen Kared, Andrew D Redd, Evan M Bloch, et al.
American Journal of Respiratory and Critical Care Medicine|January 7, 2017
Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized TrialRichard N van Zyl-Smit, Aliasgar Esmail, Mary E Bateman, et al.
American Journal of Respiratory and Critical Care Medicine|February 20, 2010
The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adultsBrian Abel, Michele Tameris, Nazma Mansoor, et al.
Vaccine|September 15, 2014
The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responsesBenjamin M N Kagina, Michele D Tameris, Hennie Geldenhuys, et al.
Pageof 4

Showing results (31-40 of 36) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 36 results.
Exercise Immunology Review|February 13, 2019
Hallmarks of improved immunological responses in the vaccination of more physically active elderly femalesGlenn Choon Lim Wong, Vipin Narang, Yanxia Lu, et al.
Biorxiv : the Preprint Server for Biology|October 14, 2020
CD8+ T cell responses in convalescent COVID-19 individuals target epitopes from the entire SARS-CoV-2 proteome and show kinetics of early differentiationHassen Kared, Andrew D Redd, Evan M Bloch, et al.
The Journal of Clinical Investigation|January 11, 2021
SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individualsHassen Kared, Andrew D Redd, Evan M Bloch, et al.
American Journal of Respiratory and Critical Care Medicine|January 7, 2017
Safety and Immunogenicity of Adenovirus 35 Tuberculosis Vaccine Candidate in Adults with Active or Previous Tuberculosis. A Randomized TrialRichard N van Zyl-Smit, Aliasgar Esmail, Mary E Bateman, et al.
American Journal of Respiratory and Critical Care Medicine|February 20, 2010
The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adultsBrian Abel, Michele Tameris, Nazma Mansoor, et al.
Vaccine|September 15, 2014
The novel tuberculosis vaccine, AERAS-402, is safe in healthy infants previously vaccinated with BCG, and induces dose-dependent CD4 and CD8T cell responsesBenjamin M N Kagina, Michele D Tameris, Hennie Geldenhuys, et al.
Pageof 4